SAN DIEGO, Nov. 30 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Nasdaq 20th Investor Program in London on Thursday, December 6, 2007 at 7:15 a.m. PT / 3:15 p.m. GMT local time in the UK. Berthold Lensker, Ph.D., Executive Director of European Operations, will be providing a corporate overview of Amylin Pharmaceuticals.
The live presentation will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate website, located at http://www.amylin.com. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.
More information about the Nasdaq 20th Investor Program is available at: http://december.nasdaqconference.com/info.asp.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and commercialization of
innovative medicines. Amylin has developed and gained approval for two
first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research and
development activities leverage the company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin is
located in San Diego, California with over 1,800 employees nationwide.
Further information on Amylin Pharmaceuticals is available at
|SOURCE Amylin Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved